glp-1 kidney receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal SGLT2 Inhibitors and GLP-1 Receptor

If you have lipedema and a BMI higher than 35, your provider may recommend bariatric surgery

Eating too quickly or consuming large portions can overwhelm the early fullness produced by GLP-1 medications or increase the risk of side effects

Gastric bypass, sleeve gastrectomy, and lap-band each alter stomach size and intestinal anatomy differently, affecting how medications move through your digestive system and where they're absorbed

A 2024 meta-analysis (Sattar et al., Lancet Diabetes Endocrinol) found that switching from semaglutide to tirzepatide produced an additional 4.2 kg mean weight loss over 40 weeks, even when semaglutide had been titrated to maximum dose

"Orange Pineapple" Product Information

2022, titled Omega-3 for the Prevention of Alcohol Use Disorder Relapse: A Placebo-Controlled, Randomized Clinical Trial, in patients transitioning out of inpatient alcohol care found that omega-3 supplementation reduced the number of drinking days at 60 and 90 days post-discharge, though this effect attenuated by 6 months